NYSE: LH · Industrial Applications and Services · 8 alerts · CIK 920148
Share price
$372.46Close, Nov 16
Market cap
$30.2B
Shares outstanding
81.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Labcorp Holdings Inc. filings on SEC EDGAR ↗
Labcorp Holdings EVP, Pres of BLS, CMO & CSO Brian J. Caveney Sells $744K of Stock
Brian J. Caveney, EVP, Pres of BLS, CMO & CSO, sold 2,000 shares of Labcorp Holdings Inc. at $372.04 a share, worth $744K in total on Nov 10, 2026. Shares held after the trade: 34,562 (-5.5%).
Labcorp Holdings EVP and President, Diagnostics Bryan T. Vaughn Sells $108K of Stock
Bryan T. Vaughn, EVP and President, Diagnostics, sold 306 shares of Labcorp Holdings Inc. at $353.70 a share, worth $108K in total on Nov 3, 2026. Shares held after the trade: 6,845 (-4.3%).
Labcorp Holdings Inc. announced that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026. The event will feature a fireside chat and a live audio webcast will be available through the company's investor relations website.
Labcorp Holdings Insider Richelle P. Parham Sells $389K of Stock
Richelle P. Parham sold 1,078 shares of Labcorp Holdings Inc. at $361.22 a share, worth $389K in total on Oct 30, 2026. Shares held after the trade: 2,288 (-32.0%).
Labcorp reported revenues of $11.1 billion for the first nine months of 2026, a 6.2% increase compared to the same period in 2025. Net earnings attributable to Labcorp Holdings Inc. rose to $839.3 million for the nine-month period, up from $711.8 million in the prior year, driven by higher operating income and lower net other expenses.
Labcorp reported third quarter 2026 revenue of $3.81 billion, a 6.9% increase year-over-year, driven by strong performance in specialty testing and strategic acquisitions. The company raised its full-year 2026 adjusted EPS guidance to a range of $18.30 to $18.70 and highlighted the FDA approval of its PGDx elio tissue complete CDx as a companion diagnostic for melanoma.
Term
Q3 2026
“Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance. We furthered our leadership in specialty testing by launching innovative tests for advanced melanoma, Alzheimer’s disease, and hepatitis D, while expanding access through strategic acquisitions across our Diagnostics and Biopharma Laboratory Services businesses.”
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend is payable on December 11, 2026, to stockholders of record as of November 24, 2026.
Labcorp is reaffirming its 2026-2029 long-term financial outlook following the release of preliminary Medicare payment rates by CMS. The company expressed concern that the proposed rates would impose steep annual cuts and is continuing to support the bipartisan RESULTS Act to ensure a sustainable laboratory system.